Volume : 11, Issue : 10, October – 2024
Title:
ANALYTICAL METHOD DEVELOPMENT & VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF GLECAPREVIR & PIBRENTASVIR IN ITS BULK AND PHARMACEUTICAL DOSAGE FORM.
Authors :
M. Ruchithasri*, Ms. R. Mounika, O. Sruthi, Dr. K. Shravankumar
Abstract :
Abstract:
A rapid and precise reverse phase High Performance Liquid Chromatographic method has been developed for the validation of Pibrentasvir and Glecaprevir, in its pure form as well as in tablet dosage form. Chromatography was carried out on a Phenomenex Gemini C18 (4.6×250mm) 5µ column using a mixture of Methanol: TEA Buffer (65:35 v/v) as the mobile phase at a flow rate of 1.0ml/min, the detection was carried out at 265nm. The retention time of the Pibrentasvir and Glecaprevir was 2.121, 3.643 ±0.02min respectively. The method produce linear responses in the concentration range of 5-25µg/ml of Pibrentasvir and 18.75-93.75µg/ml of Glecaprevir.
The method precision for the determination of assay was below 2.0%RSD. The method is useful in the quality control of bulk and pharmaceutical formulations.
Keywords: Pibrentasvir, Glecaprevir, RP-HPLC, validation.
Cite This Article:
Please cite this article in press M.Ruchithasri et al Analytical Method Development & Validation For The Simultaneous Estimation Of Glecaprevir & Pibrentasvir In Its Bulk And Pharmaceutical Dosage Form..,Indo Am. J. P. Sci, 2024; 11 (10).
Number of Downloads : 10
References:
1. Swartz ME, Jone MD, Fowler P, Andrew MA. Automated HPLC method development and transfer. LcGc N. Am, 75, 2002,49-50.
2. Synder LR, Kirkland JJ, Glajach JL. X. In Practical HPLC Methods Development. John Wiley, New York, 295, 1997,643-712.
3. Dr. Kealey and P.J Haines, Analytical Chemistry, 1stedition, Bios Publisher, (2002), P1-7.
4. A.BraithWait and F.J.Smith, Chromatographic Methods, 5thedition, Kluwer Academic Publisher, (1996), PP 1-2.
5. Andrea Weston and Phyllisr. Brown, HPLC Principle and Practice, 1st edition, Academic press, (1997), PP 24-37.
6. Yuri Kazakevich and Rosario Lobrutto, HPLC for Pharmaceutical Scientists, 1stedition, Wiley Interscience A JohnWiley & Sons, Inc., Publication, (2007), PP 15-23.
7. Chromatography, (online). URL:http://en.wikipedia.org/wiki/Chromatography.
8. Meyer V.R. Practical High-Performance Liquid Chromatography, 4thEd. England, John Wiley & Sons Ltd, (2004), PP 7-8.
9. Sahajwalla CG a new drug development, vol 141, Marcel Dekker Inc., New York, (2004), PP 421–426.
10. D. H. Shewiy, E. Kaale, P. G. Risha, B. Dejaegher, J. S. Verbeke, Y. V. Heyden, Journal Pharmaceut. Biomed. Anal, 66, 2012,11-23.
11. M. D. Rockville, General Tests, Chapter 621 – Chromatography SystemSuitability, United States Pharmacopeial Convention (USP), USP 31,2009.
12. FDA Guidance for Industry-Analytical Procedures and Method Validation, Chemistry, Manufacturing, and Controls Documentation, Center for Drug Evaluation and Research (CDER) and Centre for Biologics Evaluation and Research (CBER),2000.
13. Korany MA, Mahgoub H, Ossama TF, Hadir MM. Application of artificial neural networks for response surface modelling in HPLC method development. J Adv Res, 3, 2012,53-63.
14. Swartz M, Murphy MB. New Fronties in Chromatography. Am Lab, 37, 2005,22-27.
15. Dolan JW. Peak tailing and resolution. LcGc N. Am, 20, 2002,430-436.